Patents by Inventor Timothy F. Gallagher

Timothy F. Gallagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11912545
    Abstract: A wireless hoist system including a first hoist device having a first motor and a first wireless transceiver and a second hoist device having a second motor and a second wireless transceiver. The wireless hoist system includes a controller in wireless communication with the first wireless transceiver and the second wireless. The controller is configured to receive a user input and determine a first operation parameter and a second operation parameter based on the user input. The controller is also configured to provide, wirelessly, a first control signal indicative of the first operation parameter to the first hoist device and provide, wirelessly, a second control signal indicative of the second operation parameter to the second hoist device. The first hoist device operates based on the first control signal and the second hoist device operates based on the second control signal.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: February 27, 2024
    Assignee: Milwaukee Electric Tool Corporation
    Inventors: Matthew Post, Gareth Mueckl, Matthew N. Thurin, Joshua D. Widder, Timothy J. Bartlett, Patrick D. Gallagher, Jarrod P. Kotes, Karly M. Schober, Kenneth W. Wolf, Terry L. Timmons, Mallory L. Marksteiner, Jonathan L. Lambert, Ryan A. Spiering, Jeremy R. Ebner, Benjamin A. Smith, James Wekwert, Brandon L. Yahr, Troy C. Thorson, Connor P. Sprague, John E. Koller, Evan M. Glanzer, John S. Scott, William F. Chapman, III, Timothy R. Obermann
  • Patent number: 10298588
    Abstract: A secure communication system comprises a software program client operating on a host computing device, a service manager configured to manage client access to the protected services, an authorizer in communication between the client and the service manager, and a receiver in communication with the service manager and serves as an interface to the protected services. At least one of a browser and an application of the client is configured to access one or more protected services running on a computing device that is remote to the host computing device over a communication channel. The service manager maintains a list of predetermined services authorized for the client and limits client access to the predetermined services.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 21, 2019
    Assignee: BlackSands, Inc.
    Inventors: Dan T. Pawl, Nathan J. Pawl, Timothy F. Gallagher
  • Publication number: 20170230374
    Abstract: A secure communication system comprises a software program client operating on a host computing device, a service manager configured to manage client access to the protected services, an authorizer in communication between the client and the service manager, and a receiver in communication with the service manager and serves as an interface to the protected services. At least one of a browser and an application of the client is configured to access one or more protected services running on a computing device that is remote to the host computing device over a communication channel. The service manager maintains a list of predetermined services authorized for the client and limits client access to the predetermined services.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 10, 2017
    Inventors: Dan T. Pawl, Nathan J. Pawl, Timothy F. Gallagher
  • Patent number: 7612075
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Michael R. Myers, Wan F. Lau, Aiwen Li, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 7091204
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: August 15, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Patent number: 7026349
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: April 11, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Patent number: 6849635
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: February 1, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight, Stanley J. Schmidt
  • Publication number: 20040198979
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: October 7, 2004
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Publication number: 20040152906
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Publication number: 20040152891
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Publication number: 20040152895
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Inventors: Dashyant Dhanak, Timothy F Gallagher, Steven D Knight, Stanley J Schmidt
  • Publication number: 20040152893
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D Knight, Stanley J. Schmidt
  • Publication number: 20040142948
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Application
    Filed: November 7, 2003
    Publication date: July 22, 2004
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Publication number: 20040102450
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
    Type: Application
    Filed: July 25, 2003
    Publication date: May 27, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Publication number: 20030153604
    Abstract: This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Application
    Filed: February 24, 2003
    Publication date: August 14, 2003
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: William P. Dankulich, Daniel G. McGarry, Christopher Burns, Timothy F. Gallagher, Francis A. Volz
  • Patent number: 6541505
    Abstract: This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: April 1, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William P. Dankulich, Daniel G. McGarry, Christopher Burns, Timothy F. Gallagher, Francis A. Volz
  • Patent number: 6528512
    Abstract: This invention relates to the novel amino substituted pyrimidine compounds of Formulas (I), (II) and (III), and pharmaceutical compositions comprising a compound of these Formulas and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of inhibiting CSBP kinase and cytokines mediated by this kinase, for the treatment of cytokine mediated diseases, in mammals, by administration of a compound of Formula (I), (II) or (III).
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: March 4, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Timothy F. Gallagher, Susan M. Thompson
  • Patent number: 6361773
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: March 26, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler
  • Patent number: 6096748
    Abstract: This invention relates to the novel amino substituted pyrimidine compounds of Formulas (I), (II) and (III), and pharmaceutical compositions comprising a compound of these Formulas and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of inhibiting CSBP kinase and cytokines mediated by this kinase, for the treatment of cytokine mediated diseases, in mammals, by administration of a compound of Formula (I), (II) or (III).
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: August 1, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Timothy F. Gallagher, Susan M. Thompson
  • Patent number: 5955366
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: September 21, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, James E. Strickler, Peter R. Young